betulinic acid has been researched along with Osteoporosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhaniya, G; Gautam, S; Mishra, PR; Rai, D; Sardar, A; Sinha, S; Tripathi, AK; Trivedi, R | 1 |
| He, L; Huang, J; Jin, Y; Li, W; Li, Z; Liu, M; Luo, J; Qian, M; Qiu, W; Siwko, S; Sun, P; Tang, J; Wang, F; Wei, H; Wu, X; Wu, Z; Xiao, J; Zhao, C; Zhao, J | 1 |
2 other study(ies) available for betulinic acid and Osteoporosis
| Article | Year |
|---|---|
Nanoparticles of naturally occurring PPAR-γ inhibitor betulinic acid ameliorates bone marrow adiposity and pathological bone loss in ovariectomized rats via Wnt/β-catenin pathway.
Topics: Adiposity; Animals; beta Catenin; Betulinic Acid; Bone Marrow; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Estrogens; Female; Humans; Nanoparticles; Obesity; Osteogenesis; Osteoporosis; Ovariectomy; PPAR gamma; Rats; Wnt Signaling Pathway | 2022 |
Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice.
Topics: AMP-Activated Protein Kinases; Animals; Betulinic Acid; Cell Differentiation; Drug Delivery Systems; Estrogens; Mice; Mice, Knockout; Osteoblasts; Osteoclasts; Osteoporosis; Pentacyclic Triterpenes; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Signal Transduction; Triterpenes | 2019 |